RNAi Digest – August 2020 RNAi Digest – August 2020 Vir Biotechnology, Alnylam, Arrowhead, BMS, Novartis, Janssen reported results from their respective RNAi based therapies at key medical congresses The Digital International Liver Congress – The Annual Meeting of the […]
RNAi Digest – August 2020 RNAi Digest – August 2020 Arbutus Biopharma and Assembly Biosciences entered into an agreement to assess the combination of AB-729 (RNAi) with ABI-H0731 in patients with chronic hepatitis B 27 Aug 2020 AB-729 (RNAi targeting […]
RNAi Digest – August 2020 RNAi Digest – August 2020 Arrowhead Pharmaceuticals dosed first patient in Phase 1/2 dosing study of ARO-ENaC for Cystic fibrosis, and in a Phase 1b study of ARO-HIF2 in clear cell renal cell carcinoma (ccRCC) […]
RNAi Digest – August 2020 RNAi Digest – August 2020 Dicerna announced positive Phase 3 (PHYOX3) multidose open-label extension trial interim analysis data for nedosiran for primary hyperoxaluria (PH) 06 Aug 2020 Nedosiran (siRNA targeting LDHA) – PHYOX3 Phase 3 […]
